P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
The OP-104 Anchor Study: A Phase 1/2 Study of Safety and Efficacy of Melflufen and Dexamethasone in Combination with Either Bortezomib or Daratumumab in Patients with Rrmm; First Report on Phase 1 Data
Ludek Pour,Miquel Granell,Roman Hájek,Albert Oriol,Yvonne A. Efebera,Jacques Delaunay,Katell Le Du,Jean-Richard Eveillard,Lionel Karlin,Vladimir Maisnar,Joaquin Martinez Lopez,Maria-Victoria Mateos,Jan S. Moreb,Vincent Ribrag,Paul G. Richardson,Jan Straub,Catriona Byrne,Christian Jacques,Hanan Zubair,Enrique M. Ocio +19 more
TL;DR: The OP-104 ANCHOR phase 1/2 study was designed to evaluate melflufen and dex in triplet-combination, with either bortezomib or daratumumab in RRMM patients, and preliminary results of the phase I part were well tolerated with no reported DLTs.
Journal ArticleDOI
Strategies to overcome barriers to accrual (BtA) to NCI-sponsored clinical trials: A project of the NCI-Myeloma Steering Committee Accrual Working Group (NCI-MYSC AWG).
Matthias Weiss,Morie A. Gertz,Richard F. Little,Vincent Rajkumar,Susanna Jacobus,Rafat Abonour,Kenneth C. Anderson,Bart Barlogie,Natalie S. Callander,Edward J. Gorak,Jeffrey Matous,Glenn Mills,Robert C. Kane,Michael S. Katz,LeeAnn Jensen,James L. Omel,Robert Z. Orlowski,Paul G. Richardson,Nikhil C. Munshi +18 more
TL;DR: The NCI-MYSC AWG developed in collaboration with NCI and FDA strategies to overcome barriers to accrual to NCI clinical trials, and identified 10 potential BtA.
Journal ArticleDOI
BRAF, KIT, and NRAS testing patterns and results in metastatic melanoma.
Amy P. Abernethy,Chi Fung,Paul G. Richardson,Daniel S Eisenberg,Dominique Connolly,May Terry,Ross N Feinstein,Melisa Tucker,Catherine Miller,Leonardo Viana Nicacio +9 more
TL;DR: This retrospective, observational study studied BRAF, KIT and NRAS testing patterns in a large, longitudinal, real-world database from 118 community oncology clinics to study choice of systemic therapy.
Journal ArticleDOI
Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).
Irene M. Ghobrial,Xavier Leleu,Nancy Rubin,Wanling Xie,Fangxin Hong,Stacey Chuma,Renee Leduc,Marybeth Nelson,Kelly O’Connor,Amy Sam,Brianna Harris,Diane Warren,Peter Sportelli,Steven P. Treon,Edie Weller,Kenneth C. Anderson,Paul G. Richardson +16 more
TL;DR: Perifosine monotherapy induces a prolonged time to progression in relapsed or refractory WM, with a promising response rate of 36, stabilization of disease in 58% of pts, and manageable toxicity, as well as the convenience of oral administration.
Journal ArticleDOI
CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
Sagar Lonial,Paul G. Richardson,Donna E. Reece,Hesham Mohamed,Suresh Shelat,Jesús F. San Miguel +5 more